No Data
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Kyverna Therapeutics Names Warner Biddle CEO
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Jefferies Remains a Buy on Gilead Sciences (GILD)
This 'Forgotten Child' Is One of the Best Biotech Plays: Analyst